A Five-Year Strategic Plan to Meet the Challenges Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Office Address
11/21/2013 CURRICULUM VITAE Barry T. Katzen, M.D., FACR, FACC, FSIR OFFICE ADDRESS: Founder and Medical Director Baptist Cardiac & Vascular Institute Baptist Hospital of Miami 8900 North Kendall Drive Miami, Florida 33176 (786) 596-7050 PERSONAL INFORMATION: Marital Status: Married Children: Three EDUCATION: College: Emory University 1963-1964 Atlanta, Georgia University of Miami 1964-1966 Miami, Florida Medical School: University of Miami School of Medicine 1966-1970 Miami, Florida (early admission) Doctor of Medicine June 4, 1970 Internship: Jackson Memorial Hospital Miami, Florida (Straight Medicine) 6/24/70~6/24/71 Radiology Residency: The New York Hospital-Cornell Medical Center 1971-1974 Including: Memorial Hospital; Sloan-Kettering Cancer Institute; Hospital for Special Surgery Fellowship: St. Vincents Hospital/Medical Center Cardiovascular Radiology New York, New York 1974-1975 11/21/2013 FOREIGN STUDIES: Angiography Sept.-Nov. 1974 Policlinico Umberto Primo Instituto di Radiologia “La Sapiemza” University of Rome, Italy Plinio Rossi, M.D., Director Pulmonary Radiology and Chest Special Procedures Sept.-Oct. 1973 The Brompton Chest Hospital London, England Ian Kerr, M.D., Director FOREIGN STUDIES: Chest Pathology June-Aug. 1969 National Institute of Health Grant The Brompton Chest Hospital London, England Lynne Reid, M.D., Director LICENSURE: New York (National Boards) 1971 Florida 1970 Virginia 1976 District of Colombia 1976 CERTIFICATION: • The American Board of Radiology ~ 6/23/74 • The National Board of Medical Examiners ~ -
Gold Medal 2018
Thursday 10 May 7pm, Barbican Hall Gold Medal 2018 Finalists Ljubica Stojanovic Dan-Iulian Drut¸ac Joon Yoon Guildhall Symphony Orchestra James Judd conductor Guildhall School of Music & Drama Barbican Founded in 1880 by the Gold Medal 2018 City of London Corporation Please try to restrain from coughing until the normal breaks in the performance. Chairman of the Board of Governors Thursday 10 May 2018 If you have a mobile phone or digital watch, Deputy John Bennett 7pm, Barbican Hall please ensure that it is turned off during the Principal performance. The Gold Medal, the Guildhall School’s premier Lynne Williams In accordance with requirements of the award for musicians, was founded and endowed Vice–Principal and Director of Music licensing authority, sitting or standing in in 1915 by Sir H. Dixon Kimber Bt MA Jonathan Vaughan any gangway is not permitted. No cameras, tape recorders, other types of Please visit our website at gsmd.ac.uk Finalists recording apparatus may be brought into the auditorium. It is illegal to record any Ljubica Stojanovic piano performance unless prior arrangements Dan-Iulian Drut¸ac violin have been made with the Managing Director Joon Yoon piano and the concert promoter concerned. No eating or drinking is allowed in the The Jury auditorium. Smoking is not permitted Donagh Collins anywhere on the Barbican premises. Kathryn Enticott Paul Hughes Barbican Centre James Judd Silk St, London EC2Y 8DS Jonathan Vaughan (Chair) Administration: 020 7638 4141 Box Office Telephone Bookings: Guildhall Symphony Orchestra 020 7638 8891 (9am-8pm daily: booking fee) James Judd conductor barbican.org.uk The Guildhall School is part of Culture Mile: culturemile.london The Guildhall School is provided by the City of London Corporation as part of its contribution to the cultural life of London and the nation Gold Medal winners since 1915 Gold Medal 2018 Singers 1979 Patricia Rozario 1947 Mary O White Ljubica Stojanovic piano 1915 Lilian Stiles-Allen 1981 Susan Bickley 1948 Jeremy White Prokofiev Piano Concerto No. -
Andreas Gruentzig — the Life and Death of a Pioneer
Folia Cardiol. 2006, Vol. 13, No. 4, pp. 348–350 Copyright © 2006 Via Medica PEARLS AND GIANTS IN CARDIOLOGY ISSN 1507–4145 Andreas Gruentzig — the life and death of a pioneer The history of cardiology is rich The innovation of placing a latex with pioneers whose contributions pa- balloon in an angiographic catheter be- ved the way to the advancement of in- longs to Dr. Portman, and this trigge- vasive cardiology, but not all of them red Dr. Gruentzig to use this method have been recognized and appreciated to dilate a constricted coronary artery. for their innovations and accomplish- It took Andreas two years to solve “mi- ments. The late Andreas Gruentzig nor” technical problems from conce- was a pioneer, who was acclaimed even iving his idea till its true application. It in his lifetime, as were Forssmann, is now legendary that Gruentzig wor- Cournand and Richards, who were even ked, together with his wife Michaela, crowned by the Nobel Prize Commit- his assistant Maria Schlumpf and her tee. There were many other pioneers husband Walter, in the family kitchen whose contributions are less recognized in history, in the evenings trying many versions of the balloon like Otto Klein of Prague, while other outstanding cli- catheter. The preparations included, among other nicians whose contributions were widely known even things, cooperation with factories, chemists and during their life time, but in retrospect it seems that many other technical experts. After hundreds of unfortunately did not receive enough official recogni- experiments, Gruentzig was satisfied with the tech- tion as in the case of Charles T. -
St Luke's Cardiac History Timeline with Photos, 1903-2003
Advocate Aurora Health Advocate Aurora Health Institutional Repository Aurora St. Luke’s Medical Center Books, Documents, and Pamphlets Aurora St. Luke’s Medical Center November 2017 St Luke's Cardiac History Timeline with Photos, 1903-2003 Aurora Health Care Follow this and additional works at: https://institutionalrepository.aah.org/aslmc_books This Book is brought to you for free and open access by the Aurora St. Luke’s Medical Center at Advocate Aurora Health Institutional Repository. It has been accepted for inclusion in Aurora St. Luke’s Medical Center Books, Documents, and Pamphlets by an authorized administrator of Advocate Aurora Health Institutional Repository. For more information, please contact [email protected]. 19 03—1959 The Wright Brothers America the Beautiful z_— Ford Motor Company Picture it . America in 1903. z The west was won and the * economy was flourishing. Our nation was truly coming into its own. 1903 telephone %iJvaikee Nilie S t 0 ii C S The nations hiqenufty, hidustry and we&th teuched Mflwaukee n I 90% and as a result, akied in buikfln the cornertone.s o Harley-Davidson St. Luke’s Medical Center’s story begins A Legacy is Born in 1903 with humble roots and a vision for caring for the medical needs of Milwaukee. William F. Malone, MD. added an office wing to his castle-like mansion on the corner of Madison and Hanover (now 3rd Street) and opened Malone Hospital, the first hospital on the city’s south side. Dt Malone served as the medical director and head of surgery for the next 15 years. -
1949-2019: the 70-Year Shared Legacy of the American College of Cardiology and the Irish Cardiac Society 18Th October 2019 Galway Bay Hotel Galway, Ireland
1949-2019: The 70-Year Shared Legacy of the American College of Cardiology and the Irish Cardiac Society 18th October 2019 Galway Bay Hotel Galway, Ireland John Gordon Harold, MD MACC, MACP, FESC, FRCPI, FRCP, FCSI, FCCP, FAHA ACC Past President Disclosure Slide John Gordon Harold, MD MACC, MACP, FESC, FRCPI, FRCP (Lon), FCSI, FCCP, FAHA ACC Past President Chair, ACC Campaign for the Future Editor-in-Chief Cardiology Magazine Past Chair, ACC Board of Governors Professor of Medicine Cedars-Sinai Smidt Heart Institute and David Geffen School of Medicine No Conflicts to Report Thank You to Dr. James Crowley – President Irish Cardiac Society Seen Here With Irish President Michael D. Higgins - Galway 70th Anniversary of the American College of Cardiology and Irish Cardiac Society 1949 - 2019 Heart House, Washington DC This Talk is Dedicated to the Memory of Brian J. Maurer, MB, BCh, FACC The Tempest (1611), Act 2, Scene I History sets the context for the present… Robert I. Aitken: The Future (1935) National Archives, Washington, D.C. The Vitruvian Man (Le proporzioni del corpo umano secondo Vitruvio) da Vinci - 1490 Leonardo da Vinci (15 April 1452 – 2 May 1519) 500th Anniversary of da Vinci’s Death Back to the Future – 512 Years Ago Leonardo da Vinci -1507 • The American College of Cardiology and the Irish Cardiac Society were founded 70 years ago in 1949 during the Golden Age of Cardiology” – a time of dramatic change in cardiovascular medicine • 2019 marks the 70th anniversary of the founding of both the American College of Cardiology and the Irish Cardiac Society. -
Curriculum Vitae
CURRICULUM VITAE Name Prediman Krishan (P.K.) Shah, M.D., M.A.C.C. Business Division of Cardiology Cedars-Sinai Heart Institute and Cedars-Sinai Medical Center 127 S. San Vicente Boulevard, Suite A-3307 Los Angeles, CA 90048 EDUCATION 1962-1964 Premedical, S.P. College, Srinagar, Kashmir, India 1964-1969 Medical School, Medical College, Srinagar, Kashmir, India (M.D.) 1969-1970 Internship, S.M.H.S. Hospital of Medical College, Srinagar, Kashmir, India 1970-1971 Residency, All India Institute of Medical Sciences, New Delhi, India 1971-1972 Internship, Mount Sinai Hospital of University of Wisconsin, Milwaukee 1972-1973 Residency (Internal Medicine) Mount Sinai Hospital of University of Wisconsin, Milwaukee 1973-1974 Residency (Internal Medicine) Montefiore Hospital of Albert Einstein College of Medicine, Bronx, New York 1974-1976 Fellowship (Cardiology) Montefiore Hospital of Albert Einstein College of Medicine, Bronx, New York 1976-1977 Research Fellowship (Cardiology), Cedars-Sinai Medical Center, Los Angeles, California 1992-1993 Sabbatical and Visiting Assocaite Professor, Massachusetts General Hospital, Harvard Medical School LICENSURE State of California A 031604 DEA AS7855224 BOARD CERTIFICATION 1975 Internal Medicine 1977 Cardiology PROFESSIONAL EXPERIENCE Cedars-Sinai Medical Center 1995-2013 Director, Division of Cardiology 2 1993-present Director, Oppenheimer Atherosclerosis Research Center 2013-present Director, Atherosclerosis Prevention and Treatment Center 2011-present Director, Steven S. Cohen Fellowship Program in Atherosclerosis -
Coronary Drug- Eluting Stents
Updated BRS Data: Safety Issues and Long-Term Benefit Seo Suk Min Seoul St. Mary’s Hospital Cardiovascular Center 1 PCI and DES have revolutionized cardiovascular care 1977 1988 2001 - 2003 Andreas Gruentzig perfor Julio Palmaz and Richard Schatz de Drug-eluting stents are introduc ms the first PTCA in Zurich velop a stainless steel stent for cor ed to the European and U.S. ma , Switzerland onary applications rkets Balloon Angio Bare Coronary Drug- plasty1977 (PTCA) Metal Stents ( Eluting Stents BMS) (DES) • Continuous PCI technology advancements improved clinical outcomes for CAD • BVS represents a new approach transient vessel support with drug delivery capability without the long-term limitations of the metallic drug-eluting stents (DES) *Additional sizes received CE Mark in August 2012. 2 2 Potential Fate of Vessels Stented with DESs Delayed Healing Stent Thrombosis? * uncovered struts1 Benign, low grade, Non-occlusive Neo-Atheroma Stent Thrombosis? In-Stent Restenosis (symptomatic or asymptomatic) Late Acquired Malapposition Stent Thrombosis? 3 Information contained herein for distribution outside the U.S. only. AP2940435-OUS Rev. A 09/14 Despite improvements in PCI, there is evidence of unmet need with current treatment options Long-term BMS event rate1 Long-term DES event rate2 1. Yamaji K, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv 2010;3(5):468-75. 2. SPIRIT III: Ischemia-driven TLR through 5 years. Stone GW, TCT 2011. 4 4 Three Approaches to Improve Early and Late DES Outcomes 1. Metallic DES with bioabsorbable polymers 2. -
Viewed by Members of Our 8
COVER STORY Multivessel Stenting in the Current DES Era A case report and discussion. BY ANDREAS WALI, MD, FACC, FSCAI ntil the recent concerns about late and very late of randomized trials comparing bare-metal stents to coro- thrombosis with drug-eluting stents (DESs), the nary artery bypass grafts were underway, including ERACI II advent of these devices was greeted with great and ARTS I for multivessel coronary artery disease.18-21 These enthusiasm as one of the final tools needed for studies did not reveal any mortality benefit, and there was a Uunparalleled long-term success with percutaneous revascu- narrowing of clinical outcomes to 14% in ARTS I compared larization. The RAVEL trial,1 utilizing a sirolimus-eluting to the pre-stent CABRI. stent, revealed no in-stent restenosis in relatively simple Not long after these studies were available came news of lesions. The subsequent SIRIUS trials with sirolimus-eluting DESs with the promise of abolishing the Achilles’ heel of stents and the numerous TAXUS trials with the paclitaxel- angioplasty: restenosis. The debate continues, with surgeons eluting stents revealed marked and consistent reductions in noting that previous trials looked at highly selected patients endpoints in increasingly complex lesions.2-8 The use of at relatively low risk and preserved left ventricular function, these devices in allcomers as studied in the RESEARCH and who were not representative of the types of patients who T-SEARCH registries by Dr. Patrick W. Serruys, and the per- usually undergo surgery, and with interventionists arguing sonal experiences of interventionists with DESs, have led to that with DESs, the whole equation has changed. -
Multi-Vessel Coronary Disease and Percutaneous
Coronary disease MULTI-VESSEL CORONARY DISEASE Heart: first published as 10.1136/hrt.2003.018986 on 13 February 2004. Downloaded from AND PERCUTANEOUS CORONARY INTERVENTION 341 Cash Casey, David P Faxon Heart 2004;90:341–346. doi: 10.1136/hrt.2003.018986 he goal of percutaneous coronary intervention (PCI) is to provide a safe, effective, less invasive alternative to coronary artery bypass graft surgery (CABG). When introduced by TAndreas Gruentzig 25 years ago, he envisioned the procedure to be a technique that would delay the need for CABG until severe multi-vessel coronary disease was present. Over the years, technological advances in equipment and devices have improved safety as well as short and long term outcomes. This has greatly expanded the indications for the technique and allowed more arteries to be accessible to effective treatment with better patient outcomes. In addition, developments in adjuvant pharmacotherapy have further improved outcomes of percutaneous procedures. The results of many large trials in the 1990s have shown that percutaneous intervention can be equally successful when compared to the ‘‘gold standard’’ CABG for patients with multi-vessel coronary artery disease. Now with advances in coronary stent technology, including drug eluting stents, multi-vessel angioplasty is set to make another leap forward with further expansion of the indications and improved outcomes. Approximately two thirds of patients who require revascularisation have multi-vessel disease and two thirds of these have anatomy that is amenable to treatment by percutaneous or open heart procedures.1 Both techniques have been shown to be relatively safe and highly effective in relieving angina, and have similar mortality and myocardial infarction rates; however, all the major studies have shown fewer additional revascularisation procedures in patients who undergo open heart surgery.1 It is widely anticipated that the gap in repeat procedures may begin to close with the advent of drug eluting stents. -
Pulse of CRF the Newsletter of the Cardiovascular Research Foundation Winter 2013 - Vol 7, TCT Issue
Pulse of CRF The Newsletter of the Cardiovascular Research Foundation Winter 2013 - Vol 7, TCT Issue IN THIS ISSUE Cutting-Edge Clinical Research Presented at TCT 2013 ....................................... 1 CRF Selects Jack Lewin, MD, to Serve as President and CEO ........................ 1 In Memoriam: Andreas Gruentzig, MD, Receives TCT Career Achievement Award ..................... 2 TCT Goes Tablet ............................. 3 Cutting-Edge Clinical Research Presented at TCT 2013 The annual Transcatheter substantially reducing the need for ongoing and has enrolled nearly Cardiovascular Therapeutics (TCT) printed materials. Highlights from double the number of patients scientific symposium is the world’s the scientific sessions included: included in the current research. preeminent forum for interventional New TAVR Options on Further, the REPRISE II trial tested cardiologists, cardiac surgeons, and the safety of a second-generation vascular medicine specialists. the Horizon: TAVR device internationally. The The pivotal CoreValve Extreme Risk TCT celebrated a milestone 25 years Lotus Valve System was associated trial found that transcatheter aortic at the 2013 meeting held in San with low rates of complications in valve replacement (TAVR) with Francisco, California. Attracting over symptomatic patients with severe the CoreValve device substantially 11,500 attendees, the symposium aortic blockages who were at reduced the incidence of death broke new ground by distributing high risk for surgery. Successful and major stroke at 1 year -
Ehrs and Malpractice
A vision of tomorrow: Honoring patient choice BY RICHARD A. SZUCS, MD RRAMIFICATIONS Richard A. Szucs, MD, is a radiologist with Commonwealth Radiology, P.C., and president FALL 2013 n VOLUME 19 n NO. 4 WWW.RAMDOCS.ORG of the Board of Trustees of the Richmond Academy of Medicine. EHRs and tarting a conversation about end-of-life care can be dif- malpractice ficult, whether we are physi- BY CHIP JONES cians, patients, family mem- Secours, HCA and VCU, to advise the participants that the Richmond Sbers, religious and community leaders us regarding how we, working with Academy of Medicine assume a lead- or other professionals. It is, however, others, can promote and encourage ership role as catalyst, convener and imperative that these conversations advance care planning (ACP) in this organizer of a community-wide effort take place. And, once they occur, it is community. The core group agreed on advance care planning. Everyone equally critical that caregivers honor that adopting a uniform approach agrees that advance care planning is a patients’ choices. When no conversa- to ACP across the healthcare mar- lifelong process, best begun before a tion occurs, families and caregivers ketplace was essential for increasing crisis develops. are left making decisions that may awareness and engagement. We shared the outcomes of the As a physician, any discussion of not reflect what a patient desires. In late May 2013, the Acad- conference with health systems, electronic records should start with two The Richmond Academy of emy sponsored a community-wide Secretary of Health and Human words: “audit trail.” Here’s why: Medicine champions advance care educational conference where 100 Resources Bill Hazel, Senator Mark According to the July 2013 issue of the Virginia Medical Law Report, lawyers planning, hospice and palliative care. -
Drug Eluting Stents & Coronary Angiography
NEPALESE HEART JOURNAL Drug Eluting Stents & Coronary Angiography Dr. Bharat Rawat*, Dr. Pushpa Raj Poudel*, Dr. Smriti Mulmi* Twenty-five years ago, a young German physician, Andreas Gruentzig, inserted a catheter into a 38-year-old man's coronary artery, inflated a tiny balloon the doctor had fashioned in his own kitchen, successfully opening a blockage and restoring blood flow to a human heart. This event set a cascade of newer invention. First performed in the mid-1980s, and approved by the U.S. Food and Drug Administration (FDA) in 1994, stenting is a catheter-based procedure in which a small, expandable wire mesh tube (stent) is inserted into a diseased artery as a scaffold to hold it open. Coronary artery stents have made it possible for physicians to treat diseased coronary arteries with less trauma to the patient than coronary artery bypass graft surgery. According to 2005 guidelines issued by the American Heart Association and American College of Cardiology, stents can be considered for use in patients who have significant disease of the left main and left anterior descending coronary arteries, the two largest coronary arteries. Patients with very serious coronary artery disease, or total blockage of major arteries, are still recommended for surgery. Coronary artery stenting is almost always performed in conjunction with other catheter- based procedures, such as balloon angioplasty or atherectomy. These procedures are used to partially reduce the narrowing caused by atherosclerosis. In particular, stenting has been an important advance in balloon angioplasty. Before the introduction of stents, as many as half of all coronary arteries opened with a balloon-tipped catheter narrowed once again after the procedure (restenosis) in as much as 50% of cases.